Centauri Therapeutics Raises £24M Series A from Boehringer Ingelheim VF, Evotec and Novo Holdings' REPAIR Fund

Aurorium (formerly Vertellus) Acquires CENTAURI Technologies

March 13, 2023

Manufacturing

Aurorium (formerly Vertellus), a Pritzker Private Capital–backed specialty materials platform based in Indianapolis, acquired CENTAURI Technologies, a Pasadena, Texas–based manufacturer of specialty materials. The deal expands Aurorium’s advanced manufacturing capabilities—notably CENTAURI’s hydroformylation and hydrogenation expertise—and supports the platform’s growth across personal care, coatings, and transportation end markets.

Centauri Health Solutions Acquires Ivy Ventures, LLC

November 16, 2020

Healthcare Services

Centauri Health Solutions has acquired Virginia-based Ivy Ventures, LLC to add referral management, scheduling and analytics capabilities to its hospital revenue cycle optimization offerings. The deal, supported by Centauri's lead investor Abry Partners (with Silversmith Capital Partners and SV Health Investors also backing Centauri), brings Ivy's IP-enabled, analytics-driven referral platform and team into Centauri's growing suite of services.

Abry Partners Acquires Majority Stake in Centauri Health Solutions

January 9, 2020

Healthcare Services

Abry Partners will acquire a majority stake in Centauri Health Solutions to accelerate product development, expand sales and marketing, and pursue strategic acquisitions. Existing investors Silversmith Capital Partners and SV Health Investors will remain involved as co-investors; the transaction is expected to close in Q1 2020. Centauri is a Scottsdale, Arizona–headquartered provider of healthcare technology and services with over 1,200 employees.

XenoTherapeutics / Xeno Acquisition Corp Acquire Repare Therapeutics

January 28, 2026

Biotechnology

Repare Therapeutics has been acquired by XenoTherapeutics, Inc. and Xeno Acquisition Corp. (jointly “Xeno”) pursuant to a statutory plan of arrangement. Under the transaction, Repare shareholders received approximately US$2.20 per share plus one contingent value right (CVR) per share; the deal was approved by shareholders and the Superior Court of Québec and will result in Repare’s delisting and suspension of public reporting.

Sorrento Therapeutics Acquires ACEA Therapeutics

June 1, 2021

Biotechnology

Sorrento Therapeutics completed the acquisition of ACEA Therapeutics, making ACEA a wholly owned subsidiary and issuing Sorrento common stock plus contingent milestone and royalty payments. The deal adds multiple clinical- and preclinical-stage new chemical entities (including abivertinib) to Sorrento's oncology and immunotherapy pipeline and expands its development and manufacturing footprint in China and North America.

Novo Holdings Leads €7M Seed Investment in Bactolife

April 20, 2021

Biotechnology

Novo Holdings (via its Novo Seeds team) led a €7 million seed round in Danish biotech Bactolife, committing €5 million to advance the company's pipeline. The funding will support development and scaling of Bactolife's anti-virulence Virulence Inactivating Proteins (VIPs) for animal and human gut health; Novo's Aleks Engel will join Bactolife's board.